Traditionally, pneumonia in children is treated by oral amoxicillin in hospital facilities. Community-level health workers are not allowed to treat these children when presented at the community level. However, with the increasing patient load in the hospitals, clinicians are looking at ways to treat these patients in the community outside of hospital premises.
A clinical trial explores the safety and effectiveness of treating children 2-59 months old with chest indrawing pneumonia with a 5-day course of oral amoxicillin at the community level.
Chest-indrawing pneumonia is a type of pneumonia that affects children between the ages of 2 and 59 months. It is a severe respiratory infection that causes the chest to cave inwards while breathing. This type of pneumonia can be fatal if not treated promptly, and it is a significant cause of childhood morbidity and mortality, particularly in developing countries. Up till now the World Health Organization has recommended in-hospital treatment of all such cases, however, recently there has been a paradigm shift and physicians are now exploring out-of-hospital management of these cases especially when a referral is not feasible.
Clinical TrialThe EMPIC Study Group has conducted an innovative clinical trial for non-hypoxaemic chest-indrawing pneumonia in children. The trial aimed to test whether an enhanced community management approach could reduce the morbidity and mortality rates in these patients.
The clinical study involved 62,363 patients across four countries. Children aged 2-59 months having parents/caregivers reported cough and/or difficult breathing presenting to a community health worker were screened for enrolment in the clinical trial. The patients were divided into two groups: an intervention group and a control group.